Evidence map›Paper›PMID 31148357›Full record

ArticleThoracic cancer2019

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients.

Insu Kim, Jung Seop Eom, Eun Jung Jo, Jeongha Mok Ki Uk, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Mi-Hyun Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Insu KimDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.ORCID 0000-0001-9575-4945
Jung Seop EomDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Eun Jung JoDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Jeongha Mok Ki UkDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Kwangha LeeDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Ki Uk KimDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Hye-Kyung ParkDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Min Ki LeeDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.
Mi-Hyun KimDepartment of Internal Medicine, School of Medicine, Pusan National University, Busan, South Korea.ORCID 0000-0002-6527-6804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe presence of EGFR mutation in patients with advanced non-small cell lung cancer (NSCLC) plays an important role in determining the appropriate treatment, response, and survival. Therefore, this study attempted to predict the prognosis of NSCLC patients using data from quantitative mutation measurements.

methodsThe data of patients with advanced NSCLC who underwent EGFR mutation testing using the peptide nucleic acid (PNA) mediated clamping method at the Pusan National University Hospital from October 2015 to December 2017 were retrospectively analyzed. The efficiency of PNA clamping was determined by measuring the threshold cycle (C

resultsDuring the study period, 71 patients were treated with EGFR-tyrosine kinase inhibitors. The cutoff point for the ΔC

conclusionEGFR mutation testing using PNA clamping may predict patient survival, especially in patients with common EGFR mutations, such as exon 19 deletion or L858R. A higher ΔC

Indexed as

MutationAmino Acid SubstitutionBiomarkers, TumorCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGenetic TestingHumansLung NeoplasmsMalePeptide Nucleic AcidsPrognosisProtein Kinase InhibitorsRetrospective StudiesROC CurveSequence DeletionBiomarkers, TumorEGFR protein, humanErbB ReceptorsPeptide Nucleic AcidsProtein Kinase InhibitorsEpidermal growth factor receptorlung cancermolecular targeted therapypeptide nucleic acidprognosis

Identifiers

PMID31148357
PMCPMC6610248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.